Redpoint Bio (RPBC) Stock Price, News & Analysis

Company Overview

Redpoint Bio Corporation, a development stage biotechnology company, focuses on the development of healthier foods and new approaches for the treatment of diabetes and obesity by understanding the biology of taste and its relationship to metabolism, satiety, and diabetes. It enters into a license and commercialization agreement with International Flavors and Fragrances Inc. for the development, manufacture, use, and commercialization of RP44, which is a component of the stevia plant that works as a sweetness enhancer amplifying the existing sugary sweetness in a food or beverage. The company is based in Philadelphia, Pennsylvania.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0001
• Volume: 200,000 shs
• Average Volume: 101,150 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RPBC Stock Analysis - Frequently Asked Questions

How have RPBC shares performed this year?

Redpoint Bio's stock was trading at $0.0001 on January 1st, 2025. Since then, RPBC stock has increased by 0.0% and is now trading at $0.0001.

How do I buy shares of Redpoint Bio?

Shares of RPBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Redpoint Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Redpoint Bio investors own include Twitter (TWTR), Towne Bank (TOWN), Hershey (HSY), Ferro (FOE) and BMC Stock (BMCH).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Commercial Physical Research
• Sub-Industry: Business Services
• Current Symbol: OTCMKTS:RPBC
• CIK: 1328003
• Web: www.redpointbio.com
• Phone: 215-456-2312
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A